Cargando…
A survey of pediatric hematologists/oncologists’ perspectives on single patient Expanded Access and Right to Try
INTRODUCTION: Physicians in the United States play an essential role guiding patients through single patient pre-approval access (PAA) to investigational medical products via either the Food and Drug Administration (FDA)’s Expanded Access (EA) or the federal Right To Try (RTT) pathways. In this stud...
Autores principales: | Chapman, Carolyn Riley, Belli, Hayley M, Leach, Danielle, Shah, Lesha D, Bateman-House, Alison |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413614/ https://www.ncbi.nlm.nih.gov/pubmed/36204503 http://dx.doi.org/10.1177/23992026211005991 |
Ejemplares similares
-
Expanded Access and Right To Try Requests: The Community Oncologist's Experience
por: Zettler, Marjorie E., et al.
Publicado: (2021) -
Navigating the Expanded Access Pathway to Investigational Drugs as an Academic Oncologist
por: Fernandez Lynch, Holly, et al.
Publicado: (2023) -
Perspectives of Academic Oncologists About Offering Expanded Access to Investigational Drugs
por: Gould, Patrick, et al.
Publicado: (2022) -
A Call to action: For the attention of oncologists!
por: Ghafur, Abdul
Publicado: (2012) -
Applying spatial epidemiology to hematological disease using R: a guide for hematologists and oncologists
por: Kohno, Kei, et al.
Publicado: (2014)